406933-21-9

Basic information

• Product Name: 2-Cyano-3-trifluoromethylpyridine
• Synonyms: 2-Cyano-3-trifluoromethylpyridine;3-Trifluoromethylpicolinonitrile;3-(Trifluoromethyl)-2-picolinonitrile, 2-Cyano-3-(trifluoromethyl)pyridine;3-Trifluoromethyl-2-pyridinecarbonitrile 2-Cyano-3-trifluoromethylpyridine
• CAS NO: 406933-21-9
• Molecular Formula: C₇H₃F₃N₂
• Molecular Weight: 172.11
• Mol File: 406933-21-9.mol

Chemical Properties

• Boiling Point: 241℃
• Flash Point: 99℃
• Appearance: /
• Density: 1.37
• Vapor Pressure: 0.038mmHg at 25°C
• Refractive Index: 1.457
• Storage Temp.: Room temperature.
• PKA: -2.75±0.10(Predicted)
• CAS DataBase Reference: 2-Cyano-3-trifluoromethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyano-3-trifluoromethylpyridine(406933-21-9)
• EPA Substance Registry System: 2-Cyano-3-trifluoromethylpyridine(406933-21-9)

Safety Data

• Hazardous Substances Data: 406933-21-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyano-3-trifluoromethylpyridine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to enhance the biological activity and pharmacokinetic properties of drug candidates. Its unique structural features allow for the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Cyano-3-trifluoromethylpyridine serves as a crucial building block in the creation of novel agrochemicals, such as insecticides, herbicides, and fungicides. Its incorporation into these compounds can lead to enhanced pest control and crop protection, contributing to increased agricultural productivity.
Used in Organic Synthesis:
2-Cyano-3-trifluoromethylpyridine is utilized as a reagent in various organic synthesis processes, including cross-coupling reactions, cycloadditions, and electrophilic substitutions. Its presence in these reactions can facilitate the formation of complex molecular architectures and improve the overall yield and selectivity of the synthesized products.
Used in Medicinal Chemistry Research:
As a valuable compound in the field of medicinal chemistry, 2-Cyano-3-trifluoromethylpyridine is employed in the design and synthesis of biologically active compounds. Its unique structural features and reactivity make it an attractive candidate for the development of new drugs and therapeutic agents with potential applications in various disease areas.

InChI:InChI=1/C7H3F3N2/c8-7(9,10)5-2-1-3-12-6(5)4-11/h1-3H

Upstream product

• 557-21-1 zinc(II) cyanide 
• 65753-47-1 2-chloro-3-trifluoromethyl-pyridine 
• 3796-23-4 3-(trifluoromethyl)pyridine 
• 7677-24-9 trimethylsilyl cyanide 
• 22253-72-1 3-(trifluoromethyl)pyridine-N-oxide 
• 557-21-1 dicyanozinc 

Downstream Products

• 573762-57-9 2-cyano-3-(trifluoromethyl)-5-nitropyridine 
• 573762-62-6 5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile 
• 951753-87-0 5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile 
• 832692-66-7 7-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)-pyridin-2-yl]-1,8-naphthyridin-4-amine 
• 886371-24-0 1-[3-(trifluoromethyl)pyridin-2-yl]methanamine 
• 1396734-59-0 C₁₂H₁₅F₃N₂O₂ 
• 749257-78-1 1-[3-(trifluoromethyl)pyridin-2-yl]ethane-1-one 

Relevant articles and documents

USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII

The present invention relates to the use of strobilurin type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

Prostatic cancer treatment medicine

The invention relates to a compound with a prostatic cancer treatment function and nontoxic pharmaceutically acceptable salt of the compound. The structure of the compound is as shown in a formula I,wherein X is C or N, R1 is alkyl of C1-C3 or halogen substituted alkyl, R2 is alkyl of C1-C3 and halogen substituted alkyl or halogen, R3 and R4 are independently selected from H, alkyl and substituted alkyl, and R3 and R4 are connected to form cycloalkyl. The compound has high inhibiting effects on in-situ prostate cancer and transfer of the prostate cancer, and eclamptogenic side effects are lower.

ANDROGEN RECEPTOR MODULATOR FOR TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES

PROBLEM TO BE SOLVED: To provide a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. SOLUTION: The present invention relates to hydantoin compounds, methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example, prostate cancer, and to pharmaceutical compositions containing such compounds. In an embodiment, a pharmaceutical composition includes a therapeutically effective amount of a compound according to the formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. The present invention provides a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. These compounds can cause disappearance of prostate cancer cells and tumors. COPYRIGHT: (C)2016,JPOandINPIT

Substituted diazaspiroalkanes as androgen receptor modulators

This invention provides for compounds of the Formula II: wherein A, B, Het, R1, R2 and R3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions assoc

ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES

Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or invitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor

SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN

The present invention provides compounds of formula I: in which: one of T1and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six-or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF3, OCF3, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, nitro, cyano, isonitrile, hydroxy, C1-6alkoxy, C1-6alkylthio, -NR6R7, -CONR6R7, -COH, CO2H, C1-6alkoxycarbonyl, haloC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, C1-6alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C1-6alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.

1, 2, 5, 10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain

Compounds according to structural diagram (I) are disclosed, wherein R1, A, E and D are as defined in the specification. Also disclosed are pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram (I).